A medicine cannot be sold in the UK until the Medicines and Healthcare products Regulatory Agency has granted a marketing authorisation, and getting there means clearing clinical trials authorised by the MHRA, manufacturing the product to Good Manufacturing Practice under a Manufacturer's Authorisation, and having a Qualified Person able to certify batches. The whole of that period generates cost and no revenue, often for years. The funding question for a pre-revenue developer is therefore not which lender to approach but how to assemble enough non-dilutive and equity capital to reach the next value-inflecting milestone, because the one thing a conventional lender wants, predictable cash to service debt, is precisely what the business does not yet have.
Why senior debt does not fit pre-approval
A term lender or a working-capital provider underwrites repayment from trading cash flow, or failing that from realisable security. A clinical-stage pharma company offers neither in a form a generalist lender can price. There is no revenue to service interest. The principal asset is intellectual property whose value is contingent on trial outcomes a lender cannot assess, and a programme that reads as a breakthrough one quarter can be written to zero by a failed readout the next. Equipment and a fitted-out facility carry some security value, but financing those specific assets is a different transaction from funding the research burn around them.
So the honest answer for most pre-approval companies is that senior debt is the wrong instrument, not a deal to be negotiated harder. The runway has to be carried by capital that is paid for with equity, with future milestones, or with money that never has to be repaid at all. Spending energy chasing a cashflow loan that the numbers cannot support is time not spent on the three sources that actually fund this stage.
The non-dilutive layer: grants and R&D credits
The cheapest capital in drug development is the money you do not give equity away for. Two UK mechanisms matter most.
- Innovate UK grants. The innovation agency runs competitive funding for health, therapeutics and diagnostics, including SMART grants that support R&D projects, alongside collaborative and biomedical catalyst calls aimed at life sciences. Grant money is non-dilutive and, just as usefully, an Innovate UK award is a third-party validation signal that later equity and debt providers read closely.
- R&D tax relief. From April 2024 the old SME and RDEC schemes merged into a single above-the-line credit at a 20% headline rate. A loss-making, research-intensive SME that meets the intensity threshold can instead claim under Enhanced R&D Intensive Support, which delivers a materially higher payable credit on surrendered losses. For a pre-revenue developer with a large research spend and no profit to shelter, that payable credit is real cash back into the runway each year, not just a future tax saving. Grant funding and an R&D claim interact, so the order and structure of the two needs care to avoid clawing back relief on the grant-funded portion.
Neither source funds a whole programme, but together they stretch every pound of equity raised, which is the entire point: the fewer external pounds the runway burns, the less of the company the founders trade away to cross it.
Equity is the engine, and the tax wrappers matter
Through preclinical work and the early clinical phases, equity does the heavy lifting, from specialist life-sciences venture capital, university and angel syndicates, and patient-capital investors who accept long horizons. For earlier rounds, two HMRC-backed schemes change what a UK investor will write a cheque for.
- SEIS, the Seed Enterprise Investment Scheme, lets a qualifying young company raise up to £250,000, with investors receiving 50% income tax relief, which de-risks the earliest and riskiest money.
- EIS, the Enterprise Investment Scheme, carries 30% income tax relief and supports larger rounds. After the April 2026 uplift, standard EIS companies can raise up to £10m a year and £24m over the company's life. A company that qualifies as knowledge-intensive, which many genuine drug developers do on R&D spend and headcount, gets higher ceilings — up to £20m a year and £40m in total — and a longer window to qualify.
These wrappers are not a detail. They are often why a UK early-stage round closes at all, because the relief is what compensates a private investor for funding a binary outcome years from any return. A developer that structures its rounds to keep SEIS and then EIS eligibility intact protects its access to the deepest pool of early UK capital. Past clinical proof-of-concept, growth and crossover equity takes over as the cheque sizes outgrow the schemes.
Milestone-based venture debt: the bridge near the end of the runway
Once a company is venture-backed and approaching commercialisation, a specialist instrument can extend the runway without a full equity round: venture debt. Specialist life-sciences lenders underwrite it on pipeline strength, clinical data, the value of the intellectual property and progress against regulatory milestones rather than on current revenue, and the deal effectively leans on the existing equity investors to backstop the company. Facilities are typically structured with interest-only periods and covenants tied to specific R&D and regulatory milestones, giving the company room to reach a value-inflecting point, an approval, a trial readout, a partnering deal, before the next priced round.
The trade-off is real: venture debt carries higher rates and shorter terms than ordinary commercial debt, and it usually comes with warrants, so it is not free of dilution, only lighter than equity. Used well it is a bridge between rounds or a top-up that pushes a fundraise past a milestone at a better valuation. Used to paper over a programme that is not working, it shortens the runway it was meant to extend, because the repayment and covenants arrive whether or not the science does.
Sequencing the runway
The pattern that funds a UK developer to first lawful sale is layered, not single-source: grants and R&D credits to lower the burn, SEIS then EIS equity to fund the science and recruit private capital, growth equity once proof-of-concept is in hand, and milestone-based venture debt as a late bridge toward approval. Conventional cashflow loans and working-capital facilities belong to the chapter after marketing authorisation, when there is finally product to sell and a sales ledger to lend against. Read across the wider pharma funding routes, the discipline before approval is matching each instrument to the milestone it is meant to clear, and resisting the temptation to reach for debt the business cannot yet service.